Daniele Avenoso

Professore Associato

University of Brescia

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Daniele Avenoso is an Associate Professor at the Università degli Studi di Brescia, Italy. His research areas focus on hematopoietic stem cell transplantation, chronic graft-versus-host disease, and the economic implications of these treatments. His recent publications include studies comparing treatment modalities for myelofibrosis and examining healthcare resource utilization in patients undergoing allogeneic transplantation.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Alexandros Rampotas

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Henry Wood

King's College Hospital NHS Foundation Trust

UNITED KINGDOM

View details

Stella Bouziana

UNITED KINGDOM

View details

Juan Carlos Hernandez-Boluda

University of Valencia

SPAIN

View details

Jennifer Davidson

Head of Research, Specialty EMR

UNITED KINGDOM

View details

Piers Patten

King’s College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniele Avenoso

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Healthcare Resource Utilization and Associated Costs in Patients With Chronic Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation in England

Modern views of nutritional support in patients undergoing allogeneic stem cell transplantation

Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies

Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study

Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma.

Collaborators (6)

Alexandros Rampotas

Henry Wood

Stella Bouziana

Juan Carlos Hernandez-Boluda

Jennifer Davidson

Piers Patten

Make your next move.